Ophiasis Alopecia Areata in a Patient With Spondyloarthritis on Secukinumab: A Case Report and Review of the Literature
February 2024
in “
Curēus
”
TLDR Secukinumab can cause hair loss, which may improve after stopping the medication.
Secukinumab, an IL-17A-targeting biological agent used for treating spondyloarthritis, can cause alopecia areata (AA) as a rare adverse effect. This case report details a 46-year-old female with SpA who developed an ophiasis pattern of AA while on secukinumab, with hair regrowth observed after discontinuing the medication. The report discusses the patient's clinical course, potential pathophysiological mechanisms, and reviews similar cases in the literature, emphasizing the need for awareness and management of secukinumab-induced AA and further research into tailored treatments.
